Montelukast improves air trapping, not airway remodeling, in patients with moderate-to-severe asthma: A pilot study

Chinese Medical Journal

Volumn 126, Issue 12, 2013, Pages 2229-2234

  Gao, Jin Ming ^a   Cai, Feng ^a   Peng, Min ^a   Ma, Yi ^a   Wang, Bin ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Air trapping; Airway remodeling; Asthma; High resolution computed tomography; Lung function

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; MONTELUKAST; PLACEBO;

ADULT; AIRWAY; ARTICLE; ASTHMA; BEDTIME DOSAGE; BODY PLETHYSMOGRAPHY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION TEST; MALE; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESIDUAL VOLUME; TOTAL LUNG CAPACITY;

ACETATES; ADULT; AIRWAY REMODELING; ANTI-ASTHMATIC AGENTS; ASTHMA; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; PILOT PROJECTS; QUINOLINES; TOTAL LUNG CAPACITY;

EID: 84879270913     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20121888     Document Type: Article

References (33)

1. Wenzel SE, Busse WW. Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119: 14-21.
2. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). (Accessed June 1, 2012 at: http://www.ginaasthma.org.)
3. Scichilone N, Battaglia S, Olivieri D, Bellia V. The role of small airways in monitoring the response to asthma treatment: what is beyond FEV1? Allergy 2009; 64: 1563-1569.
4. Burgel PR. The role of small airways in obstructive airway diseases. Rur Respir Rev 2011; 20: 23-33.
5. In't Veen JC, Beekman AJ, Bel EH, Sterk PJ. Recurrent exacerbations in severe asthma are associated with enhanced airway closure during stable episodes. Am J Respir Crit Care Med 2000; 161: 1902-1906.
6. Diamant Z, Sampson AP. Anti-inflammatory mechanisms of leukotriene modulators. Clin Exp Allergy 1999; 29: 1449-1453.
7. Diamant Z, Mantzouranis E, Bjermer L. Montelukast in the treatment of asthma and beyond. Expert Rev Clin Immunol. 2009; 5: 639-658.
8. Kraft M, Cairns CB, Ellison MC, Pak J, Irvin C, Wenzel S. Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast. Chest 2006; 130; 1726-1732.
9. Zeidler MR, Kleerup EC, Goldin JG, Kim HJ, Truong DA, Simmons MD, et al. Montelukast improves regional air-trapping due to small airways obstruction in asthma. Eur Respir J 2006; 27: 307-315.
10. Bozek A, Warkocka-Szoltysek B, Filipowska-Gronska A, Jarzab J. Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. J Asthma 2012; 49: 530-534.
11. Gono H, Fujimoto K, Kawakami S, Kubo K. Evaluation of airway wall thickness and air trapping by HRCT in asymptomatic asthma. Eur Respir J 2003; 22: 965-971.
12. de Jong PA, Müller NL, Paré PD, Coxson HO. Computed tomographic imaging of the airways: relationship to structure and function. Eur Respir J 2005; 26: 140-152.
13. Busacker A, Newell Jr JD, Keefe T, Hoffman EA, Granroth JC, Castro M, et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest 2009; 135: 48-56.
14. Standardization of spirometry-1987 update. Official statement of American Thoracic Society. Respiratory Care 1987; 32: 1039-1060.
15. Sorkness RL, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Chung KF, et al; National Heart, Lung, and Blood Institute Severe Asthma Research Program. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008; 104: 394-403.
16. Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: does it matter? J Allergy Clin Immunol 2009; 124 (6 suppl): 88S-93S.
17. Lahzami S, King GG. Targeting small airways in asthma: the new challenge of inhaled corticosteroid treatment. Eur Respir J 2008; 31: 1145-1147.
18. Cohen J, Douma WR, ten Hacken NH, Vonk JM, Oudkerk M, Postma DS. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J 2008; 31: 1213-1220.
19. Figueroa DJ, Breyer RM, Defoe SK, Kargman S, Daugherty BL, Waldburger K, et al. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med 2001; 163: 226-233.
20. Hay DW. Pharmacology of leukotriene receptor antagonists. More than inhibitors of bronchoconstriction. Chest 1997; 111 (2 suppl): 35S-45S.
21. Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994; 149: 953-959.
22. Pavord ID, Ward R, Woltmann G, Wardlaw AJ, Sheller JR, Dworski R. Induced sputum eicosanoid concentrations in asthma. Am J Respir Crit Care Med 1999; 160:1905-1909.
23. Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, et al. Clinical outcomes with montelukast as a partner agent to corticosteroid therapy (COMPACT) international study group. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58: 211-216.
24. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011; 364: 1695-1707.
25. Farah CS, King GG, Brown NJ, Downie SR, Kermode JA, Hardaker KM, et al. The role of the small airways in the clinical expression of asthma in adults. J Allergy Clin Immunol 2012; 129: 381-387.
26. Wagner EM, Liu MC, Weinmann GG, Permutt S, Bleecker ER. Peripheral lung resistance in normal and asthmatic subjects. Am Rev Respir Dis 1990; 141: 584-588.
27. Mechiche H, Naline E, Candenas L, Pinto FM, Birembault P, Advenier C, et al. Effects of cysteinyl leukotrienes in small human bronchus and antagonist activity of montelukast and its metabolites. Clin Exp Allergy 2003; 33: 887-894.
28. Laurent F, Latrabe V, Raherison C, Marthan R, Tunon-de-Lara JM. Functional significance of air trapping detected in moderate asthma. Eur Radiol 2000; 10: 1404-1410.
29. Elias JA, Zhu Z, Chupp G, Homer RJ. Airway remodeling in asthma. J Clin Invest 1999; 104: 1001-1006.
30. Henderson WR Jr, Tang LO, Chu SJ, Tsao SM, Chiang GK, Jones F, et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 2002; 165: 108-116.
31. Henderson WR Jr, Chiang GK, Tien YT, Chi EY. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med 2006; 173: 718-728.
32. Kelly MM, Chakir J, Vethanayagam D, Boulet LP, Laviolette M, Gauldie J, et al. Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest 2006; 130: 741-753.
33. Ohno Y, Koyama H, Yoshikawa T, Nishio M, Matsumoto S, Iwasawa T, et al. Pulmonary magnetic resonance imaging for airway diseases. J Thorac Imaging 2011; 26: 301-316.